Expression of PTTG1 and TET1 in hepatocarcinoma tissues and its relationship with clinico-pathological parameters

doi:10.3877/cma.j.issn.1674-0793.2021.01.004

Abstract

Abstract:

Objective

To investigate the correlation between the expression levels of pituitary tumor transforming gene 1 (PTTG1) and ten-eleven translocation 1 (TET1), and the clinicopathological parameters in liver cancer tissues and paracancer tissues, and to provide theoretical basis for the prediction of the occurrence and development of liver cancer.

Methods

From February 2017 to January 2019, 129 cases of hepatocellular carcinoma specimens undergoing radical resection in Central Hospital of Enshi Tujia and Miao Autonomous Prefecture were selected as the experimental group, and 129 corresponding adjacent tissues were selected as the control group. Immunohistochemistry technique was used to detect the expression of PTTG1 and TET1 in the two groups. The relationship between the clinicopathological parameters and the expression of PTTG1 and TET1 was analyzed. In addition, the relationship between the PTTG1 protein and TET1 protein was correlation analyzed.

Results

The high expression rate of PTTG1 in hepatocellular carinoma tissues (53.5%, 69/129) was significantly higher than that in adjacent tissues (1.6%, 2/129) (χ²=84.646, P<0.001). The expression of TET1 in hepatocellular carinoma tissues (45.0%, 58/129) was significantly lower than that in adjacent tissues (81.4%, 105/129) (χ²=35.255, P<0.001). The expression level of PTTG1 was negatively correlated with that of TET1 (r= -0.726, P<0.001). The expression level of PTTG1 was closely related to satellite nodules and Edmondson pathological grade (P<0.05), and the expression level of TET1 was closely related to the tumor envelope status and satellite nodules (P<0.05).

Conclusion

PTTG1 protein and TET1 protein are expressed abnormally in hepatocellular carcinoma tissues, and are closely correlated with the occurrence and development of hepatocellular carcinoma, which suggests PTTG1 protein and TET1 protein can be used as biological indicators for the diagnosis and prognosis of hepatocellular carcinoma.

Key words: Liver neoplasms, PTTG1, TET1, Immunohistochemistry, Clinical pathological parameters

Qinghe Li, Jiayao Zhang, Bin Fan, Yu Wang. Expression of PTTG1 and TET1 in hepatocarcinoma tissues and its relationship with clinico-pathological parameters[J]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(01): 18-22.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2021.01.004

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2021/V15/I01/18

Figures/Tables 2

References 21

[1]	Trinchet JC. Hepatocellular carcinoma in 2014: current situation and future prospects[J]. Diagn Interv Imaging, 2014, 95(7-8): 705-708.
[2]	Moriguchi M, Umemura A, Itoh Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma[J]. Clin J Gastroenterol, 2016, 9(4): 184-190.
[3]	高春. 肝癌分子病理流行病学[J]. 世界华人消化杂志, 2018, 26(9): 557-563.
[4]	石兆鹏，陈琳琳，杜娟, 等. 小鼠TET1蛋白核定位信号的预测与鉴定[J]. 中国生物化学与分子生物学报, 2016, 32(11): 1227-1233.
[5]	Li L, Han LY, Yu M, et al. Pituitary tumor-transforming gene 1 enhances metastases of cervical cancer cells through miR-3666-regulated ZEB1[J]. Tumour Biol, 2015, 37(12): 15567-15573.
[6]	程志祥，江平，孙权, 等. TET1在肝癌组织中的表达及临床意义[J]. 武汉大学学报（医学版）, 2018, 39(6): 914-917.
[7]	Fromowitz FB, Viola MV, Chao S, et al. ras p21 expression in the progression of breast cancer[J]. Hum Pathol, 1987, 18(12): 1268-1275.
[8]	田斐，王捷夫，战阳, 等. 不同危险分级中央型肝癌患者术后临床病理特点及预后分析[J]. 中国肿瘤临床, 2018, 45(22): 1133-1141.
[9]	沙菲菲，田轩，周浩雄, 等. PTTG1在D-GalN/TNF-α所致LO2肝细胞损伤中的变化及对细胞凋亡的影响[J]. 新医学, 2020, 51(4): 261-266.
[10]	Zhang J, Yang Y, Chen L, et al. Overexpression of pituitary tumor transforming gene (PTTG) is associated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma[J]. Acta Histochem, 2014, 116(3): 435-439.
[11]	Zhang E, Liu S, Xu Z, et al. Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in oral squamous cell carcinoma (OSCC) and promotes migration, invasion and epithelial-mesenchymal transition (EMT) in SCC15 cells[J]. Tumour Biol, 2014, 35(9): 8801-8811.
[12]	Tian YP, Zhu YM, Sun XH, et al. Multiple functions of Ten-eleven translocation 1 during tumorigenesis[J]. 中华医学杂志（英文版）, 2016, 129(14): 1744-1751.
[13]	禤婕滢，郭云蔚，周浩雄. 垂体肿瘤转化基因1在肝细胞癌患者中的表达及意义[J/CD]. 中华肝脏外科手术学电子杂志, 2018, 7(5): 426-430.
[14]	张霹雲，王斌，王军, 等. 5-甲基胞嘧啶羟化酶TET1在肝再生时卵圆细胞向肝细胞分化过程中的作用[J]. 第三军医大学学报, 2014, 36(8): 797-801.
[15]	Ellermeier C, Vang S, Cleveland K, et al. Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors[J]. Anticancer Res, 2014, 34(8): 3957-3967.
[16]	段建华，陈鉴，钱燕敏, 等. 三氧化二砷对肝癌细胞表达PTTG1和VEGF的影响及其意义[J]. 国际消化病杂志, 2012, 32(2): 114-117.
[17]	Huang Y, Chavez L, Chang X, et al. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells[J]. Proc Natl Acad Sci U S A, 2014, 111(4): 1361-1366.
[18]	Huang H, Jiang X, Wang J, et al. Identification of MLL-fusion/MYC miR-26 TET1 signaling circuit in MLL-rearranged leukemia[J]. Cancer Letters, 2016, 372(2): 157-165.
[19]	王传旭，刘传亮，史光军. TET1在肝癌组织中的表达及对HepG2细胞生物学行为的影响[J]. 山东医药, 2018, 58(13): 36-38.
[20]	Chen HF, Wu KJ. Epigenetics, TET proteins, and hypoxia in epithelial-mesenchymal transition and tumorigenesis[J]. Biomedicine (Taipei), 2016, 6(1): 1.
[21]	Rea M, Gripshover T, Fondufe-Mittendorf Y. Selective inhibition of CTCF binding by iAs directs TET-mediated reprogramming of 5-hydroxymethylation patterns in iAs-transformed cells[J]. Toxicol Appl Pharmacol, 2018, 338: 124-133.

临床参数		例数	PTTG1蛋白				TET1蛋白
临床参数		例数	低表达	高表达	χ²值	P值	低表达	高表达	χ²值	P值
性别					0.254	0.614			0.607	0.436
	男	104	50(48.1)	54(51.9)			55(52.9)	49(47.1)
	女	25	10(40.0)	15(60.0)			16(64.0)	9(36.0)
年龄(岁)					0.009	0.925			0.009	0.922
	≤40	65	30(46.2)	35(53.8)			35(53.8)	30(46.2)
	> 40	64	30(46.9)	34(53.1)			36(56.3)	28(43.7)
血清甲胎蛋白(μg/L)					0.369	0.544			<0.001	0.996
	≤25	30	12(40.0)	18(60.0)			16(53.3)	14(46.7)
	> 25	99	48(48.5)	51(51.5)			55(55.6)	44(44.4)
乙肝表面抗原					1.486	0.223			<0.001	0.998
	阴性	10	5(50.0)	5(50.0)			5(50.0)	5(50.0)
	阳性	119	55(46.2)	64(53.8)			66(55.5)	53(44.5)
肝硬化					0.117	0.733			1.778	0.182
	无或轻度	89	40(44.9)	49(55.1)			45(50.6)	44(49.4)
	中-重度	40	20(50.0)	20(50.0)			26(65.0)	14(35.0)
ICGR15					0.031	0.861			0.811	0.368
	≤10%	87	40(46.0)	47(44.0)			45(51.7)	42(48.3)
	> 10%	42	20(47.6)	22(52.4)			26(61.9)	16(38.1)
临床分期					0.025	0.873			0.010	0.921
	Ⅰ	45	20(44.4)	25(55.6)			25(55.6)	20(44.4)
	Ⅱ	84	40(47.6)	44(52.4)			46(54.8)	38(45.2)
肿瘤大小(cm)					0.661	0.416			0.518	0.472
	≤5	50	26(52.0)	24(48.0)			30(60.0)	20(40.0)
	> 5	79	34(43.0)	45(57.0)			41(51.9)	38(48.1)
肿瘤包膜					0.025	0.873			46.020	<0.001
	完整	84	39(46.4)	45(53.6)			65(77.4)	19(22.6)
	无或不完整	45	21(46.7)	24(53.3)			6(13.3)	39(86.7)
卫星结节					27.952	<0.001			49.442	<0.001
	无	87	55(63.2)	32(36.8)			67(77.0)	20(23.0)
	有	42	5(11.9)	37(88.1)			4(9.5)	38(90.5)
Edmondson病理分级					30.132	<0.001			0.358	0.550
	Ⅰ~Ⅱ	83	54(65.1)	29(34.9)			48(57.8)	36(43.4)
	Ⅲ~Ⅳ	46	6(13.0)	40(87.0)			23(50.0)	23(50.0)

临床参数		例数	PTTG1蛋白				TET1蛋白
临床参数		例数	低表达	高表达	χ²值	P值	低表达	高表达	χ²值	P值
性别					0.254	0.614			0.607	0.436
	男	104	50(48.1)	54(51.9)			55(52.9)	49(47.1)
	女	25	10(40.0)	15(60.0)			16(64.0)	9(36.0)
年龄(岁)					0.009	0.925			0.009	0.922
	≤40	65	30(46.2)	35(53.8)			35(53.8)	30(46.2)
	> 40	64	30(46.9)	34(53.1)			36(56.3)	28(43.7)
血清甲胎蛋白(μg/L)					0.369	0.544			<0.001	0.996
	≤25	30	12(40.0)	18(60.0)			16(53.3)	14(46.7)
	> 25	99	48(48.5)	51(51.5)			55(55.6)	44(44.4)
乙肝表面抗原					1.486	0.223			<0.001	0.998
	阴性	10	5(50.0)	5(50.0)			5(50.0)	5(50.0)
	阳性	119	55(46.2)	64(53.8)			66(55.5)	53(44.5)
肝硬化					0.117	0.733			1.778	0.182
	无或轻度	89	40(44.9)	49(55.1)			45(50.6)	44(49.4)
	中-重度	40	20(50.0)	20(50.0)			26(65.0)	14(35.0)
ICGR15					0.031	0.861			0.811	0.368
	≤10%	87	40(46.0)	47(44.0)			45(51.7)	42(48.3)
	> 10%	42	20(47.6)	22(52.4)			26(61.9)	16(38.1)
临床分期					0.025	0.873			0.010	0.921
	Ⅰ	45	20(44.4)	25(55.6)			25(55.6)	20(44.4)
	Ⅱ	84	40(47.6)	44(52.4)			46(54.8)	38(45.2)
肿瘤大小(cm)					0.661	0.416			0.518	0.472
	≤5	50	26(52.0)	24(48.0)			30(60.0)	20(40.0)
	> 5	79	34(43.0)	45(57.0)			41(51.9)	38(48.1)
肿瘤包膜					0.025	0.873			46.020	<0.001
	完整	84	39(46.4)	45(53.6)			65(77.4)	19(22.6)
	无或不完整	45	21(46.7)	24(53.3)			6(13.3)	39(86.7)
卫星结节					27.952	<0.001			49.442	<0.001
	无	87	55(63.2)	32(36.8)			67(77.0)	20(23.0)
	有	42	5(11.9)	37(88.1)			4(9.5)	38(90.5)
Edmondson病理分级					30.132	<0.001			0.358	0.550
	Ⅰ~Ⅱ	83	54(65.1)	29(34.9)			48(57.8)	36(43.4)
	Ⅲ~Ⅳ	46	6(13.0)	40(87.0)			23(50.0)	23(50.0)

Please choose a citation manager

Content to export